Jun. 5 at 12:50 PM
$FOLD is one of the very few comm'l-stage non-oncology focused bios whose share price has not recovered from the lows in the XBI back in early April 2025 (during the tariff related sell-offs).
This is truly disappointing as FOLD trades at one of the lowest multiples of FY2028 analyst consensus revenue estimates in its peer group (peer commercial-stage non-oncology focused bios doing
$500MM to
$1.0B/year in sales) at a healthy 90% gross margin.
Should FOLD's share price not recover then FOLD's BOD needs to consider a sale to maximize shareholder value. Per Centerview Partners, SWTX's peer group were acquired at 2.3X to 5.2X Year 4 (FY28 for FOLD) projected revenues. This would be gains of 32 to 200% versus FOLD's market cap today.
FOLD trades at 1.7X FY28 consensus where peer commercial-stage non-oncology focused bios trade at a much higher multiple of FY28 consensus include
$MIRM $BCRX &
$CPRX (2.7 to 3.8X)
Only
$SRPT trades at a lower multiple (we know why).
This is not investment advice
